BEM-100

BEM-100 is a multi-target drug candidate currently in preclinical development by Shanghai Benemae Pharmaceutical (also known as Renhui Biology) for the treatment of metabolic diseases. The drug is designed to address the complex pathophysiology of metabolic disorders by simultaneously modulating multiple biological pathways, potentially offering enhanced therapeutic efficacy compared to single-target agents. As part of the developer's metabolic pipeline, which focuses on recombinant protein and peptide engineering, BEM-100 is being investigated for its potential in managing conditions such as obesity and type 2 diabetes. Specific molecular targets for the candidate have not yet been publicly disclosed, but the program leverages the company's expertise in incretin-based therapies.